Carsten C. Skarke

faculty photo
Adjunct Associate Professor of Medicine
Robert L. McNeil, Jr Fellow in Translational Medicine, Institute for Translational Medicine and Therapeutics, University of Pennsylvania
Director, CTSA Translational Research Internship Program (TRIP), Institute for Translational Medicine and Therapeutics, University of Pennsylvania
Sr. Research Investigator , Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania Perelman School of Medicine
Department: Medicine

Contact information
Institute for Translational Medicine and Therapeutics (ITMAT)
University of Pennsylvania Perelman School of Medicine
Smilow Center for Translational Research 10-101
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 573-0673
MD (Medicine)
Johannes Gutenberg-University School of Medicine, Mainz, Germany, 1998.
Dr. med. (Pathology)
Johannes Gutenberg-University School of Medicine, Mainz, Germany, 2000.
Post-Graduate Training
Postdoctoral Fellow, Institute of Clinical Pharmacology, Center for Drug Research, Development and Safety (ZAFES), Johann Wolfgang Goethe-University Frankfurt am Main, Germany, 2000-2005.
Alexander von Humboldt Fellow, Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2007-2011.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Human Clock Biology: Dr. Skarke is studying the human chronobiome under basal and perturbed conditions integrating multiomics, clinical and remote sensing outputs. These reference data are necessary to interrogate the time dependence in the incidence or severity of disease phenotypes.

Human Phenomics: Dr. Skarke uses an array of mobile apps and wearable devices to collect behavioral, physiological and environmental data for correlation with multiomics datasets.

Ongoing Pilot Projects:

I) Circadian Clocks & HIV Infection.
The aim is to explore if HIV patients experience disruptions in circadian clock function.

II) Circadian Clocks & Shift Work.
The goal is to explore whether disruptions of the microbiome contribute to disease risk of shift workers.

III) Circadian Clocks & Surgical Interventions.
We wish to explore whether personalized prehabilitation improves post-operative outcomes and reduces circadian rhythm disruption.

IV) Circadian Clocks & Asthma & Air Pollution.
The objective is to study the impact of diurnally fluctuating air pollutants on asthma disease expression in the context of human biorhythms.
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Human Lipid Biology: Dr. Skarke is pursuing the question whether the specialized pro-resolving mediators are formed in humans in concentrations of biological relevance.

Fish Oil Supplements: Dr. Skarke examines the effects of omega-3 fatty acids on markers of oxidative stress and cardiovascular function under conditions perturbed by alcohol.

Drug Development: Dr. Skarke characterizes the clinical pharmacology of the novel COX-2 inhibitor CG100649 (now Polmacoxib).

Selected Publications

Carsten Skarke, Nicholas Lahens, Seth Rhoades, Amy Campbell, Kyle Bittinger, Aubrey Bailey, Christian Hoffmann, Randal S. Olson, Lihong Chen1, Guangrui Yang, Thomas S. Price, Jason H. Moore, Frederic D. Bushman, Casey S. Greene, Gregory R. Grant, Aalim M. Weljie & Garret A. FitzGerald : A Pilot Characterization of the Human Chronobiome. Scientific Reports 7(1): 17141:1-12, December 2017 Notes: Cited 25 times; Altmetric score of 108.

G. A. Fitzgerald, G. Yang, G. K. Paschos, X. Liang & C. Skarke: Molecular clocks and the human condition: approaching their characterization in human physiology and disease. Diabetes, Obesity and Metabolism 17(Suppl. 1): 139–142, September 2015.

Bhavna N. Desai, Garima Singhal, Mikiko Watanabe, Darko Stevanovic, Thomas L. Lundasen, Marie Mather, Hilde G. Verdeh, Folliott M. Fisher, Andrew C. Adams, Imad A. Nasser, Gerald A. FitzGerald, Jeffrey S. Flier, Carsten Skarke, Eleftheria Maratos-Flier: Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Molecular Metabolism. Elsevier, 6(11): 1395-1406, November 2017 Notes: Dr. Skarke is co-senior author.

Carsten Skarke, Naji Alamuddin, John A. Lawson, Xuanwen Li, Jane F. Ferguson, Muredach P. Reilly and Garret A. FitzGerald: Bioactive products formed in humans from fish oils. Journal of Lipid Research 56(9): 1808-20, September 2015 Notes: Featured in a commentary in the same JLR issue; press coverage (Medical Research, Cardiology Today); cited 61 times; Altmetric score of 70.

Sarapee Hirankarn, Jeffrey S. Barrett, Naji Alamuddin, Garret A. FitzGerald, Carsten Skarke: GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies. Clinical Pharmacology in Drug Development 2(4): 379–386, July 2013 Notes: DOI: 10.1002/cpdd.47.

Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, FitzGerald GA: Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther 91(6): 986-93, June 2012.

Skarke Carsten, FitzGerald Garret A: Training translators for smart drug discovery. Science Translational Medicine. American Association for the Advancement of Science, 2(26): 26cm12, April 2010.

back to top
Last updated: 02/08/2021
The Trustees of the University of Pennsylvania